Reblozyl (Luspatercept-Aamt) coverage
Customize your policy alerts
Sign up for sierra health and life Policy 2026D0084L alerts
Get alerted when Policy 2026D0084L changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity and authorization criteria for Reblozyl (luspatercept-aamt) for UnitedHealthcare Commercial and Individual Exchange benefit plans, covering specific hematologic indications in adults.
Template updated and content transferred to a shared policy template; Application section added specifying that the policy applies to UnitedHealthcare Commercial and Individual Exchange benefit plans.
Background, Clinical Evidence, and References sections updated to reflect the most current information.
Coverage Criteria for Reblozyl (luspatercept-aamt)
Initial Therapy — Beta thalassemia
Covered when ALL of the following are met
Continuation Therapy — Beta thalassemia
Covered when ALL of the following are met
Initial Therapy — Myelodysplastic Syndromes (MDS)
Covered when ALL of the following are met
MDS initial
- Option A: Both: ring sideroblasts < 15% (or <5% with SF3B1 mutation) AND serum erythropoietin ≤ 500 mU/mL
- Option B: Ring sideroblasts ≥ 15% (or ≥5% with SF3B1 mutation)
Continuation Therapy — MDS
Covered when ALL of the following are met
Initial Therapy — MDS/MPN overlap
Covered when ALL of the following are met
Continuation Therapy — MDS/MPN overlap
Covered when ALL of the following are met
Initial Therapy — Myelofibrosis-associated anemia
Covered when ALL of the following are met
Myelofibrosis initial
- Option A: Both: symptomatic splenomegaly and/or constitutional symptoms AND used in combination with a JAK inhibitor (examples: fedratinib, ruxolitinib, momelotinib, pacritinib)
- Option B: No splenomegaly or constitutional symptoms
Continuation Therapy — Myelofibrosis-associated anemia
Covered when ALL of the following are met
Continuation Therapy — Continuation of Therapy
Continuation of Therapy
Applies to continuation/reauthorization only
FDA Indications
FDA-Indicated Uses (informational; approval alone not basis for coverage)
Informational only; FDA approval alone is not a basis for coverage
Compendia-based recommendations
NCCN recommended uses (informational)
NCCN defines lack of response as <1.5 g/dL hemoglobin rise or no decrease in transfusion requirement by 6–8 weeks
Reblozyl (luspatercept‑aamt) is not proven or medically necessary for the treatment of the following conditions: alpha thalassemia, beta thalassemia in pediatric patients, non‑transfusion dependent beta thalassemia, and sickle beta thalassemia (HbS/beta thalassemia). Requests for coverage for these diagnoses may be denied.
In addition, UnitedHealthcare follows the NCCN Drugs and Biologics Compendium framework: indications with NCCN Categories of Evidence and Consensus of 3 are considered unproven and not medically necessary. Use of Reblozyl for any indication classified as Category 3 by NCCN is therefore considered not covered.
Providers should not submit authorization requests for the conditions listed above as medically necessary uses. When a requested indication corresponds to an NCCN Category 3 recommendation, coverage is not supported. Documentation submitted for these indications will be reviewed but is likely to result in a denial based on the policy’s stated exclusions.
Specifically, use of Reblozyl for the listed thalassemia subtypes and for pediatric beta thalassemia is considered not medically necessary. Prior authorization requests for these populations are expected to be excluded from coverage under this policy.
Coding and Diagnostic References
| J0896 | Injection, luspatercept-aamt, 0.25 mg. |
| D46.1 | Refractory anemia with ring sideroblasts. |
| D46.20 | Refractory anemia with excess of blasts, unspecified. |
| D46.21 | Refractory anemia with excess of blasts 1. |
| D46.22 | Refractory anemia with excess of blasts 2. |
| D46.B | Refractory cytopenia with multilineage dysplasia and ring sideroblasts. |
| D56.1 | Beta thalassemia. |
| D56.5 | Hemoglobin E-beta thalassemia. |
Provider Requirements, Documentation, and Prior Authorization
Authorization duration and renewal
Prior authorization is required for initial and continuation/reauthorization requests. Initial approvals and any reauthorization will be for no more than 12 months.
- Initial authorization will be for no more than 12 months.
- Reauthorization will be for no more than 12 months.
Prior authorization and reauthorization — required documentation
Obtain prior authorization and include documentation of the clinical indication, the member’s response for continuation requests, that the drug is prescribed by or in consultation with an appropriate specialist, and that dosing follows FDA‑approved labeling.
- Document the indication (diagnosis meeting the policy criteria).
- For continuation/reauthorization, provide evidence of positive clinical response (see continuation documentation requirements).
- Confirm prescribing clinician is a hematologist/oncologist or specialist experienced in the relevant disease and that dosing is per FDA labeling.
- HCPCS J0896 may be used for billing reference.
Clinical pre-assessment — ring sideroblasts and EPO
For lower‑risk MDS eligibility, document ring sideroblast assessment and a serum erythropoietin (EPO) level as applicable to the diagnostic pathway in the policy.
- Ring sideroblasts percentage (e.g., ≥15% or <15%; note RS <5% with SF3B1 mutation qualifies in specified subgroups).
- Serum erythropoietin level (policy uses threshold ≤ 500 mU/mL where applicable).
Response evaluation (informational)
NCCN describes lack of response to luspatercept as failure to achieve a ≥1.5 g/dL hemoglobin rise or failure to decrease RBC transfusion requirement by 6 to 8 weeks; use these criteria to interpret treatment effect though the policy does not mandate a specific step‑therapy algorithm.
- NCCN defines lack of response as <1.5 g/dL hemoglobin rise or no decrease in transfusion requirement by 6–8 weeks.
Required documentation for initial and renewal requests
Include documentation that supports the diagnosis, shows specialist involvement, confirms dosing per FDA labeling, and provides evidence of clinical benefit (e.g., reduced transfusion burden or increased hemoglobin) when submitting an authorization request.
- Supportive diagnostic documentation meeting the policy’s disease‑specific criteria (e.g., transfusion history, IPSS‑R category, SF3B1 status, platelet count where applicable).
- Record that Reblozyl is prescribed by or in consultation with a hematologist/oncologist or other appropriate specialist.
- Confirm dosing is in accordance with the FDA‑approved labeling.
Required documentation for continuation
For continuation/reauthorization, document a positive clinical response to Reblozyl such as a reduction in transfusion burden or an increase in hemoglobin from baseline and indicate the timing of the response relative to treatment.
- Specify the clinical benefit observed (e.g., number of transfusions avoided, change in units transfused, hemoglobin rise) and the timepoint when measured.
- Confirm continued prescribing by or consultation with an appropriate specialist and that dosing remains per FDA labeling.
Not covered indications — denial risk
Requests for Reblozyl to treat alpha thalassemia, beta thalassemia in pediatric patients, non‑transfusion‑dependent beta thalassemia, or sickle beta thalassemia are considered not proven/not medically necessary and may be denied.
- Alpha thalassemia is listed as not proven/not medically necessary.
- Beta thalassemia in pediatric patients is listed as not proven/not medically necessary.
- Non‑transfusion dependent beta thalassemia is listed as not proven/not medically necessary.
- Sickle beta thalassemia (HbS/beta thalassemia) is listed as not proven/not medically necessary.
Excluded indications — basis for denial
Requests for Reblozyl for alpha thalassemia, pediatric beta thalassemia, non–transfusion‑dependent beta thalassemia, or sickle beta thalassemia are expressly excluded as not proven/not medically necessary and may be denied.
- Alpha thalassemia.
- Beta thalassemia in pediatric patients.
- Non–transfusion‑dependent beta thalassemia.
- Sickle beta thalassemia (HbS/beta thalassemia).
Background and Clinical Context
Reblozyl (luspatercept‑aamt) is an erythroid maturation agent indicated to treat anemia in certain hematologic disorders. This policy clarifies that, despite FDA and compendia statements for specific adult indications, Reblozyl is not covered for the thalassemia subtypes and pediatric beta thalassemia listed above and follows NCCN categorizations when determining whether compendia recommendations constitute proven, medically necessary uses.
Definitions and Key Terms
Line of Therapy and Treatment Positioning
informational
Informational
first-line | second-line
Informational
Biomarker and Laboratory Requirements
Permitted Regimens and Dosing
| Regimen | Indication | Coverage status |
|---|---|---|
| Combination with a JAK inhibitor (examples: fedratinib, ruxolitinib, momelotinib, pacritinib) | ||
| Myelofibrosis-associated anemia with symptomatic splenomegaly and/or constitutional symptoms; used in combination with a JAK inhibitor as specified | ||
| Covered when used in combination with a JAK inhibitor for myelofibrosis-associated anemia with symptomatic splenomegaly/constitutional symptoms |
| Regimen | Indication | Coverage status |
|---|---|---|
| Monotherapy per FDA labeling | ||
| Myelofibrosis-associated anemia without splenomegaly or constitutional symptoms (monotherapy per FDA label) | ||
| Covered as monotherapy per FDA labeling for patients without splenomegaly/constitutional symptoms |
| Regimen | Dosing (as studied / per FDA label) | Indication | Coverage status |
|---|---|---|---|
| Subcutaneous luspatercept every 3 weeks | |||
| Starting dose 1.0 mg/kg with possible titration up to 1.75 mg/kg (as in MEDALIST and COMMANDS trials); administered subcutaneously every 3 weeks per FDA labeling | |||
| Lower-risk MDS with symptomatic anemia (ESA‑naive or ESA‑failure depending on subgroup); dosing and titration per trials and FDA label | |||
| Covered when dosed subcutaneously every 3 weeks with starting dose 1.0 mg/kg and titration to 1.75 mg/kg as appropriate per FDA labeling and trial protocols |
| Regimen | Dosing (as studied) | Indication | Coverage status |
|---|---|---|---|
| Subcutaneous luspatercept once every 3 weeks (BELIEVE trial regimen) | |||
| Administered subcutaneously once every 3 weeks for the duration of observed transfusion reduction (as in BELIEVE); trial included adults receiving 6-20 RBC units per 24 weeks with no transfusion-free period >35 days | |||
| Transfusion‑dependent beta thalassemia in adults (meeting trial transfusion criteria) | |||
| Covered when used as in the BELIEVE trial: subcutaneous dosing every 3 weeks for adults meeting transfusion‑dependent criteria |
Policy Revision History
Policy content transferred to a shared policy template; Application section added to state the policy applies to UnitedHealthcare Commercial and Individual Exchange benefit plans; Background, Clinical Evidence, and References updated to reflect current information.
Previous policy versions 2025D0084K and IEXD0084.09 were archived.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.